Simon T. Bedford

Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1)

D.S. Williamson, Garrick P. Smith, P. Acheson-Dossang et al. · Journal of Medicinal Chemistry · 2017 · 47 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Identification of novel,<i>in vivo</i>active Chk1 inhibitors utilizing structure guided drug design

Andrew J. Massey, S.P. Stokes, Helen Browne et al. · Oncotarget · 2015 · 45 citations · Full text

Medicine, Oncology, Pharmacology +13

Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase

Paul A. Brough, Lisa Baker, Simon T. Bedford et al. · Journal of Medicinal Chemistry · 2017 · 38 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +13

Design and Synthesis of Pyrrolo[2,3-<i>d</i>]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate

D.S. Williamson, Garrick P. Smith, Gitte Kobberøe Mikkelsen et al. · Journal of Medicinal Chemistry · 2021 · 38 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor

Simon T. Bedford, Karen Benwell, Teresa Brooks et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 10 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11